138 results on '"Rink, Lori"'
Search Results
2. Supplementary Table S2 from SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
3. Data from SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
4. SAR-096: Phase II clinical trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS)
5. Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case
6. Supplementary Table 2 from Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor
7. Supplementary Table 1 from Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor
8. Supplementary Figure Legend from Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor
9. Supplementary File 7 from Detection of Treatment-Induced Changes in Signaling Pathways in Gastrointestinal Stromal Tumors Using Transcriptomic Data
10. Data from Detection of Treatment-Induced Changes in Signaling Pathways in Gastrointestinal Stromal Tumors Using Transcriptomic Data
11. Free Article from Detection of Treatment-Induced Changes in Signaling Pathways in Gastrointestinal Stromal Tumors Using Transcriptomic Data
12. Supplementary File 3- Processed Tumor Data from Detection of Treatment-Induced Changes in Signaling Pathways in Gastrointestinal Stromal Tumors Using Transcriptomic Data
13. Supplementary File 1 from Detection of Treatment-Induced Changes in Signaling Pathways in Gastrointestinal Stromal Tumors Using Transcriptomic Data
14. Supplementary File 2- Preprocessed Cell Line Data from Detection of Treatment-Induced Changes in Signaling Pathways in Gastrointestinal Stromal Tumors Using Transcriptomic Data
15. Supplementary File 6 from Detection of Treatment-Induced Changes in Signaling Pathways in Gastrointestinal Stromal Tumors Using Transcriptomic Data
16. Supplementary File 5- Transcription p Values for all Cell Line Analysis from Detection of Treatment-Induced Changes in Signaling Pathways in Gastrointestinal Stromal Tumors Using Transcriptomic Data
17. File 4-qRT-PCR Validation from Detection of Treatment-Induced Changes in Signaling Pathways in Gastrointestinal Stromal Tumors Using Transcriptomic Data
18. Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion
19. Insulin-Like Growth Factor 1 Receptor Is a Potential Therapeutic Target for Gastrointestinal Stromal Tumors
20. Combined Inhibition of AKT and KIT Restores Expression of Programmed Cell Death 4 (PDCD4) in Gastrointestinal Stromal Tumor
21. Outcomes in the dedifferentiated liposarcoma cohort of SAR-096, a phase II trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS).
22. Clinical and molecular characteristics of gastrointestinal stromal tumors in the pediatric and young adult population
23. Identification of Wee1 as a target in combination with avapritinib for gastrointestinal stromal tumor treatment
24. Identification of Wee1 as Target in Combination with Avapritinib for the Treatment of Gastrointestinal Stromal Tumor
25. SAR-096: A phase II trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS).
26. Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study
27. Creation and characterization of a novel human PDGFRA D842V-mutant GIST cell line.
28. Additional file 1: of Succinate dehydrogenase deficiency in a PDGFRA mutated GIST
29. Abstract 4808: Combinations of imatinib mesylate with AKT inhibitor (miransertib, ARQ 751) or FGFR inhibitor (derazantinib) show synergy in GIST cell lines and preclinical models
30. Abstract A02: Succinate dehydrogenase deficiency in a PDGFRA mutated gastrointestinal stromal tumor
31. Integrating Blended Learning into the Language Classroom
32. Succinate dehydrogenase deficiency in a PDGFRA mutated GIST
33. Additional file 1: Table S1. of Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case
34. Additional file 2: Table S2. of Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case
35. Choosing reading texts for the language classroom: Is simplification a complication?
36. Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor
37. Over-expression of IGF1R and Frequent Mutational Inactivation of SDHA in Wild-type SDHB-negative Gastrointestinal Stromal Tumors
38. Results of SARC 022, a phase II multicenter study of linsitinib in pediatric and adult wild-type (WT) gastrointestinal stromal tumors (GIST).
39. Evaluating new therapies in gastrointestinal stromal tumor using in vivo molecular optical imaging
40. Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: a retrospective study
41. Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion
42. Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma
43. Abstract 3927: Evaluating new therapies in Gastrointestinal Stromal Tumor using in vivo molecular optical imaging.
44. ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor
45. Overexpression of insulin‐like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild‐type SDHB‐negative gastrointestinal stromal tumors
46. ACRIN 6665/RTOG 0132 Phase II Trial of Neoadjuvant Imatinib Mesylate for Operable Malignant Gastrointestinal Stromal Tumor: Monitoring with 18F-FDG PET and Correlation with Genotype and GLUT4 Expression
47. Detection of Treatment-Induced Changes in Signaling Pathways in Gastrointestinal Stromal Tumors Using Transcriptomic Data
48. High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors
49. Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor
50. The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.